Innovent Biologics and Spero Therapeutics have entered into a global license agreement for IBI355 (SP001), a third-generation Fc-silent anti-CD40L antibody. Under the terms of the deal, Innovent is eligible to receive up to a total of US$1.1B that includes an upfront payment, and is eligible to receive development, regulatory and commercial milestone payments. This deal enables Innovent to focus on advancing the next-generation of therapies for IgG4-related disease and Spero will have exclusive rights to develop, manufacture, and commercialise IBI355 (SP001) globally, excluding China.